Faisal Khurshid
Stock Analyst at Leerink Partners
(4.17)
# 519
Out of 4,996 analysts
25
Total ratings
60%
Success rate
15.26%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTNM Contineum Therapeutics | Initiates: Outperform | $20 | $11.92 | +67.79% | 1 | Sep 25, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $73 | $67.42 | +8.28% | 1 | Sep 12, 2025 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $2.28 | -12.28% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $99.16 | +2.86% | 2 | Jul 10, 2025 | |
| ABCL AbCellera Biologics | Assumes: Outperform | $5 | $4.74 | +5.49% | 1 | Jul 7, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $1.39 | -28.06% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $16.24 | +177.09% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $8.93 | +79.17% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.52 | +31.58% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $0.84 | +1,803.63% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 | $56.25 | +6.67% | 2 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $93.05 | -14.02% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $2.41 | +522.41% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $7 | $8.77 | -20.18% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $16.76 | +168.50% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $24 | $33.78 | -28.95% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.29 | +442.64% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $5.53 | +44.67% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.94 | +432.42% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $5.26 | +109.13% | 1 | Mar 21, 2023 |
Contineum Therapeutics
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $11.92
Upside: +67.79%
Protagonist Therapeutics
Sep 12, 2025
Initiates: Outperform
Price Target: $73
Current: $67.42
Upside: +8.28%
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $2.28
Upside: -12.28%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $99.16
Upside: +2.86%
AbCellera Biologics
Jul 7, 2025
Assumes: Outperform
Price Target: $5
Current: $4.74
Upside: +5.49%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $1.39
Upside: -28.06%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $16.24
Upside: +177.09%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $8.93
Upside: +79.17%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.52
Upside: +31.58%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $0.84
Upside: +1,803.63%
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $56.25
Upside: +6.67%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $93.05
Upside: -14.02%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $2.41
Upside: +522.41%
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $8.77
Upside: -20.18%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $16.76
Upside: +168.50%
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $33.78
Upside: -28.95%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.29
Upside: +442.64%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $5.53
Upside: +44.67%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.94
Upside: +432.42%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $5.26
Upside: +109.13%